Skip to Main Content

vTv Therapeutics Inc. Class A Common Stock

VTVT Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
VTVT Income Statement
VTVT Balance Sheet
VTVT Cash Flow

Recent trades of VTVT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
VTVT Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
VTVT Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
VTVT Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by VTVT's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof Sep. 17, 2024
  • Patent Title: Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs May. 07, 2024
  • Patent Title: Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine Apr. 30, 2024
  • Patent Title: Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine Jan. 30, 2024
  • Patent Title: Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs Dec. 05, 2023
  • Patent Title: Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof May. 16, 2023
  • Patent Title: Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine Dec. 13, 2022
  • Patent Title: Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine Aug. 23, 2022
  • Patent Title: Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists Aug. 23, 2022
  • Patent Title: Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof Sep. 28, 2021
  • Patent Title: Use of a ppar-δ agonist for reducing loss of muscle strength, muscle mass, or type i muscle fibers in an immobilized limb Aug. 24, 2021
  • Patent Title: Glucokinase activator compositions for the treatment of diabetes Apr. 20, 2021
  • Patent Title: Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs Mar. 23, 2021
  • Patent Title: Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists Mar. 16, 2021
  • Patent Title: Bach1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof Jan. 26, 2021
  • Patent Title: Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof Jan. 12, 2021
  • Patent Title: Glucokinase activator compositions for the treatment of diabetes Mar. 17, 2020
  • Patent Title: Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof Feb. 25, 2020
  • Patent Title: Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors Feb. 25, 2020
  • Patent Title: Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists Nov. 12, 2019
  • Patent Title: Bach1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof Nov. 05, 2019
  • Patent Title: Use of a ppar-δ agonist for reducing loss of muscle strength, muscle mass, or type i muscle fibers in an immobilized limb Oct. 29, 2019
  • Patent Title: Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors Aug. 27, 2019
  • Patent Title: Piperidine derivative and methods of use thereof Jul. 30, 2019
  • Patent Title: Compositions comprising metformin and a glucokinase activator Jul. 30, 2019
  • Patent Title: Substituted imidazole derivatives and methods of use thereof Jul. 30, 2019
  • Patent Title: Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof May. 14, 2019
  • Patent Title: Bach1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof Jan. 08, 2019
  • Patent Title: Tricyclic compounds as modulators of tnf-α synthesis and as pde4 inhibitors Oct. 02, 2018
  • Patent Title: Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator Sep. 04, 2018
  • Patent Title: Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof Jul. 24, 2018
  • Patent Title: Glucokinase activator compositions for the treatment of diabetes Jun. 26, 2018
  • Patent Title: Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type i muscle fibers in an immobilized limb May. 15, 2018
  • Patent Title: Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists Jan. 02, 2018
  • Patent Title: Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator Jan. 02, 2018
  • Patent Title: Tricyclic compounds as modulators of tnf-α synthesis and as pde4 inhibitors Dec. 05, 2017
  • Patent Title: Treatment of mild and moderate alzheimer's disease Aug. 01, 2017
  • Patent Title: Compounds that modulate oxidative stress Jul. 18, 2017
  • Patent Title: Tricyclic compounds as modulators of tnf-α synthesis and as pde4 inhibitors Jun. 27, 2017
  • Patent Title: Phenoxy acetic acids and phenyl propionic acids as pparδ agonists May. 30, 2017
  • Patent Title: Substituted imidazole derivatives and methods of use thereof Mar. 21, 2017
  • Patent Title: Use of a ppar-delta agonist for treating muscle atrophy Nov. 08, 2016
  • Patent Title: Compounds that modulate oxidative stress Sep. 20, 2016
  • Patent Title: Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors Jul. 19, 2016
  • Patent Title: Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator Jun. 07, 2016
  • Patent Title: Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof Dec. 01, 2015
  • Patent Title: Substituted azoanthracene derivatives and intermediates for preparation thereof Nov. 03, 2015
  • Patent Title: Tricyclic compounds as modulators of tnf-α synthesis and as pde4 inhibitors Oct. 20, 2015
  • Patent Title: Phenylglyoxylic acid derivatives and their preparation and use Oct. 20, 2015
  • Patent Title: Oxadiazoanthracene compounds for the treatment of diabetes Sep. 01, 2015
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of VTVT in WallStreetBets Daily Discussion

VTVT News

Recent insights relating to VTVT

CNBC Recommendations

Recent picks made for VTVT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in VTVT

VTVT Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view VTVT Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top